Bio-Techne
William Blair Initiates Coverage of Bio-Techne With Outperform Rating
The investment bank emphasized Bio-Techne's position in multiple high-growth and attractive end markets, including cell and gene therapy, spatial biology, and liquid biopsy.
Top Five Articles on GenomeWeb Last Week: Agilent, Bruker, Foundation Medicine, More
Last week, GenomeWeb's readers were most interested in Agilent Technologies announcing that it is discontinuing its Resolution Bioscience business.
Sylvester Comprehensive Cancer Center Wins $2.5M NCI Grant to Develop Prostate Cancer Test
The team will work with collaborators at Bio-Techne's Exosome Diagnostics to develop its prostate cancer biomarker on a new platform.
Bio-Techne, Akoya End Partnership to Develop Automated Spatial Biology Workflow
The companies announced in 2022 that they would work to enable automated workflows for RNAscope tests on Akoya's spatial phenotyping systems.
The company said on Tuesday that its fiscal fourth quarter revenues rose 5 percent and full-year 2023 revenues climbed 3 percent.